Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | Overcoming poor myeloma prognosis

Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone Health, New York, NY, tells us about the poor prognosis many multiple myeloma patients receive and the benefits of molecular techniques such as the use of daratumumab and IMiDs at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.